Antidotes for factor Xa inhibitors and methods of using the same
AssigneePortola Pharmaceuticals, Inc.
InventorsGenmin Lu, David R. Phillips, Patrick Andre, Uma Sinha
Life of this patent
Estimating the term…
Abstract
The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Claims18
An isolated two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 13 or an amino acid sequence having at least 95% sequence identity to SEQ ID NO. 13, wherein the amino acid sequence having at least 95% sequence identity (a) has reduced procoagulant activity compared to wild-type factor Xa, (b) is capable of binding to a factor Xa inhibitor and (c) does not assemble into a prothrombinase complex.
An isolated two-chain polypeptide comprising the amino acid sequence of SEQ ID NO. 13.
An isolated two-chain polypeptide consisting essentially of the amino acid sequence of SEQ ID NO. 13.
Dependencies are inferred from the claim text.